Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160

1992 ◽  
Vol 12 (6) ◽  
pp. 429-439 ◽  
Author(s):  
David C. Montefiori ◽  
◽  
Barney S. Graham ◽  
Srisakul Kliks ◽  
Peter F. Wright
Keyword(s):  
Vaccinia Virus ◽  
Recombinant Vaccinia Virus ◽  
Serum Antibodies ◽  
Recombinant Vaccinia ◽  
Hiv 1

Cross-Neutralizing Antibodies in Rabbits Immunized with HIV-1 gp160 Purified from Simian Cells Infected with a Recombinant Vaccinia Virus

1991 ◽  
Vol 7 (10) ◽  
pp. 791-798 ◽  
Author(s):  
JAMES KLANIECKI ◽  
TRACY DYKERS ◽  
BRUCE TRAVIS ◽  
ROBERT SCHMITT ◽  
MORGAN WAIN ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Neutralizing Antibodies ◽  
Recombinant Vaccinia Virus ◽  
Recombinant Vaccinia ◽  
Hiv 1

scholarly journals Induction of a Mucosal Cytotoxic T-Lymphocyte Response by Intrarectal Immunization with a Replication-Deficient Recombinant Vaccinia Virus Expressing Human Immunodeficiency Virus 89.6 Envelope Protein

1998 ◽  
Vol 72 (10) ◽  
pp. 8264-8272 ◽  
Author(s):  
Igor M. Belyakov ◽  
Linda S. Wyatt ◽  
Jeffrey D. Ahlers ◽  
Patricia Earl ◽  
C. David Pendleton ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Vaccinia Virus ◽  
T Lymphocyte ◽  
Envelope Protein ◽  
Cytotoxic T Lymphocyte ◽  
Recombinant Vaccinia Virus ◽  
Mucosal Immunization ◽  
Recombinant Vaccinia ◽  
Immunodeficiency Virus ◽  
Hiv 1

ABSTRACT To improve the safety of recombinant vaccinia virus vaccines, modified vaccinia virus Ankara (MVA) has been employed, because it has a replication defect in most mammalian cells. Here we apply MVA to human immunodeficiency virus type 1 (HIV-1) vaccine development by incorporating the envelope protein gp160 of HIV-1 primary isolate strain 89.6 (MVA 89.6) and use it to induce mucosal cytotoxic-T-lymphocyte (CTL) immunity. In initial studies to define a dominant CTL epitope for HIV-1 89.6 gp160, we mapped the epitope to a sequence, IGPGRAFYAR (from the V3 loop), homologous to that recognized by HIV MN loop-specific CTL and showed that HIV-1 MN-specific CTLs cross-reactively recognize the corresponding epitope from strain 89.6 presented by H-2Dd. Having defined the CTL specificity, we immunized BALB/c mice intrarectally with recombinant MVA 89.6. A single mucosal immunization with MVA 89.6 was able to elicit long-lasting antigen-specific mucosal (Peyer’s patch and lamina propria) and systemic (spleen) CTL responses as effective as or more effective than those of a replication-competent vaccinia virus expressing 89.6 gp160. Immunization with MVA 89.6 led to (i) the loading of antigen-presenting cells in vivo, as measured by the ex vivo active presentation of the P18-89.6 peptide to an antigen-specific CTL line, and (ii) the significant production of the proinflammatory cytokines (interleukin-6 and tumor necrosis factor alpha) in the mucosal sites. These results indicate that nonreplicating recombinant MVA may be at least as effective for mucosal immunization as replicating recombinant vaccinia virus.

scholarly journals Screening of HIV-1 Env Glycoproteins for the Ability to Raise Neutralizing Antibody Using DNA Immunization and Recombinant Vaccinia Virus Boosting

Virology ◽  
1997 ◽  
Vol 230 (2) ◽  
pp. 265-274 ◽  
Author(s):  
J.F.L. Richmond ◽  
F. Mustafa ◽  
S. Lu ◽  
J.C. Santoro ◽  
J. Weng ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Neutralizing Antibody ◽  
Recombinant Vaccinia Virus ◽  
Dna Immunization ◽  
Recombinant Vaccinia ◽  
Hiv 1

HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides

Nature ◽  
1988 ◽  
Vol 336 (6198) ◽  
pp. 484-487 ◽  
Author(s):  
Douglas F. Nixon ◽  
Alain R. M. Townsend ◽  
John G. Elvin ◽  
Charles R. Rizza ◽  
John Gallwey ◽  
...  
Keyword(s):  
T Lymphocytes ◽  
Vaccinia Virus ◽  
Cytotoxic T Lymphocytes ◽  
Synthetic Peptides ◽  
Recombinant Vaccinia Virus ◽  
Recombinant Vaccinia ◽  
Hiv 1

scholarly journals Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques

2015 ◽  
Vol 23 (3) ◽  
pp. 204-212 ◽  
Author(s):  
Rajesh Thippeshappa ◽  
Baoping Tian ◽  
Brad Cleveland ◽  
Wenjin Guo ◽  
Patricia Polacino ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Immune Responses ◽  
Vaccinia Virus ◽  
Protective Efficacy ◽  
Recombinant Vaccinia Virus ◽  
Oral Immunization ◽  
Recombinant Vaccinia ◽  
Immunodeficiency Virus ◽  
Vaccinia Viruses ◽  
Hiv 1

ABSTRACTHuman immunodeficiency virus type 1 (HIV-1) acquisition occurs predominantly through mucosal transmission. We hypothesized that greater mucosal immune responses and protective efficacy against mucosal HIV-1 infection may be achieved by prime-boost immunization at mucosal sites. We used a macaque model to determine the safety, immunogenicity, and protective efficacy of orally delivered, replication-competent but attenuated recombinant vaccinia viruses expressing full-length HIV-1 SF162 envelope (Env) or simian immunodeficiency virus (SIV) Gag-Pol proteins. We examined the dose and route that are suitable for oral immunization with recombinant vaccinia viruses. We showed that sublingual inoculation of two vaccinia virus-naive pigtailed macaques with 5 × 108PFU of recombinant vaccinia viruses was safe. However, sublingual inoculation with a higher dose or tonsillar inoculation resulted in secondary oral lesions, indicating the need to optimize the dose and route for oral immunization with replication-competent vaccinia virus vectors. Oral priming alone elicited antibody responses to vaccinia virus and to the SF162 Env protein. Intramuscular immunization with the SF162 gp120 protein at either 20 or 21 weeks postpriming resulted in a significant boost in antibody responses in both systemic and mucosal compartments. Furthermore, we showed that immune responses induced by recombinant vaccinia virus priming and intramuscular protein boosting provided protection against intrarectal challenge with the simian-human immunodeficiency virus SHIV-SF162-P4.

scholarly journals Purification of recombinant vaccinia virus-expressed monomeric HIV-1 gp120 to apparent homogeneity

2013 ◽  
Vol 90 (1) ◽  
pp. 34-39 ◽  
Author(s):  
Wenjin Guo ◽  
Brad Cleveland ◽  
Thaddeus M. Davenport ◽  
Kelly K. Lee ◽  
Shiu-Lok Hu
Keyword(s):  
Vaccinia Virus ◽  
Recombinant Vaccinia Virus ◽  
Recombinant Vaccinia ◽  
Apparent Homogeneity ◽  
Hiv 1

An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1env gene recombinant vaccinia virus

1992 ◽  
Vol 126 (1-4) ◽  
pp. 11-20 ◽  
Author(s):  
J. E. S. Hansen ◽  
H. Clausen ◽  
S. L. Hu ◽  
J. O. Nielsen ◽  
S. Olofsson
Keyword(s):  
Vaccinia Virus ◽  
Recombinant Vaccinia Virus ◽  
Recombinant Vaccinia ◽  
Neutralization Epitope ◽  
Gp 120 ◽  
Gene Recombinant ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document